Gemfibrozil
Gemfibrozil
Definition
A fibric acid derivative with hypolipidemic effects. Gemfibrozil interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III results in subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).
Also known as GEMFIBROZIL, Lopid — per NCIT
Also identified as
- ATC C10AB04 per RXNORM
- NCIT NCIT:C29071 per NCIT
- SCTID 35282000 per RXNORM
- SCTID 387189002 per RXNORM
- UNII Q8X02027X3 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Coronary artery disorder | may prevent | MEDRT · Public domain (U.S. Government work) |
| Coronary artery disorder | may treat | MEDRT · Public domain (U.S. Government work) |
| Hyperlipoproteinemia | may treat | MEDRT · Public domain (U.S. Government work) |
| Hypertriglyceridemia | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Cardiovascular system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Heart | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.